Among those with blood cancers — including myeloma, lymphoma, and leukemia — only 59% fully understand their diagnosis, data from England’s National Cancer Patient Experience…
Myeloma
The U.S. Food and Drug Administration (FDA) has approved Adaptive Biotechnologies’ clonoSEQ Assay to detect and monitor minimal residual disease (MRD) — the…
A combination of Oncolytics Biotech’s investigational therapy Reolysin (pelareorep) with anti-cancer medication Opdivo (nivolumab) and standard of care will be tested in…
The U.S. Food and Drug Administration has approved a combination of once-weekly Kyprolis (carfilzomib), developed by Amgen, and dexamethasone for the treatment of multiple…
Molecular Templates has partnered with Takeda to develop engineered toxin bodies (EBTs) — a next-generation immuno-oncology therapy that delivers toxic payloads to cancer cells — targeting the…
The European Medicines Agency has validated Bristol-Myers Squibb’s application for Empliciti (elotuzumab), in combination with Pomalyst (pomalidomide) and low-dose dexamethasone, for the treatment of…
Updated results from a Phase 2b clinical trial continue to support Karyopharm Therapeutics‘ investigative oral therapy selinexor (KPT-330) as a promising approach for heavily-treated multiple myeloma…
In an effort to inform multiple myeloma patients and their loved ones about cutting-edge research and what it means for them, Patient Power…
SELLAS Life Sciences’ lead therapy candidate galinpepimut-S (GPS) received orphan medicinal product designation from the European Medicines Agency for the treatment of multiple myeloma…
Leukogene Therapeutics, a startup company from the Medical University of South Carolina (MUSC), has been awarded a $2 million Small Business Technology…
